BioArctic Neuroscience receives major grant from EU
The Swedish biopharmaceutical company BioArctic Neuroscience AB is developing a novel treatment for complete spinal cord injury. This project has received funding (6.4 M€) from the ...
News
2nd US patent granted for therapeutic antibodies for Parkinson’s disease
On October 14th 2014 the US patent office granted BioArctic a 2nd US patent (US 8859501) covering therapeutic antibodies for Parkinson’s disease.
BioArctic Neuroscience receives grant from VINNOVA
In September 2014, VINNOVA announced that BioArctic Neuroscience AB together with the Ångström Laboratory, Department of Engineering Sciences, Uppsala University, and Psilox AB were granted up ...
US patent granted on therapeutic antibodies for Parkinson’s disease
The US patent office has granted BioArctic a US patent (US 8809506) covering therapeutic and diagnostic antibodies for Parkinson’s disease and Dementia with Lewy Bodies.
...
BioArctic´s new facilities inaugurated
Last week, on April 28, BioArctic´s new offices and labs were inaugurated by Ewa Björling, Minister for Trade, Ministry for Foreign Affairs.
Biogen Idec invests together with Eisai in BioArctic´s antibody BAN2401 for treatment of Alzheimer´s disease
AGREEMENT TO ENHANCE R&D CAPABILITIES AIMED AT CREATING NEW THERAPIES TO SUPPRESS ALZHEIMER’S DISEASE PROGRESSION
US patent issued for protofibril-binding antibodies for treatment and diagnostics of Parkinson’s Disease, Dementia with Lewy Bodies and other Alpha-Synucleinopathies
The US patent office has granted a BioArctic patent for protofibril-binding antibodies and their use in therapeutic and diagnostic methods for Parkinson's Disease, Dementia with Lewy ...
BioArctic Neuroscience AB has a new CEO and has moved to new premises
BioArctic´s mission is to provide new and effective treatments for patients with disorders in the Central Nervous System. The company has evolved in a very positive ...